Don't overlook the fact that MedicNova listed mipsagargin as a investigative drug in the recent patent update. MediNovas drug MN-166 (ibudilast) is involved in numerous clinical trials and has orphan status for Glioblastoma. Mipsagargin has information about its clinical benefit from its own PH II trial for Glioblastoma. The combination of Mipsagargin as a front line drug to halt progression and MN-166 to administer the knock out punch would be a major advancement in the treatment for this disease.
Market Data 
Markets 
AI
